Locus Biosciences is a healthcare company focusing on CRISPR-engineered precision antibacterial platforms, efficient bacteriophage delivery, and revolutionizing the treatment of bacterial diseases. Based in Morrisville, NC, the company combines the antibacterial power of CRISPR-Cas3 with the safe delivery of bacterial viruses called bacteriophage. This enables physicians to begin treatment more quickly, resulting in better medical outcomes.
Founded in 2015 by CEO Paul Garofolo, Locus Biosciences is dedicated to protecting humanity against the threat of disease through the development of novel precision medicines. The company is relatively small, with only 75 employees, but it has an annual revenue of $3 million. With its mission and innovative approach to health care, Locus Biosciences continues to work towards improving the lives of people suffering from bacterial infections.
